Two loci, TRPC6 and CBR3, were associated with cardiac events in the NSABP B-31 patients and analyses suggest that both associations are the effects of chemotherapy rather than trastuzumab and further extend the evidence for both as putative risk genes for doxorubicin-induced heart failure. Here, TRPC6 is linked to heart failure.